Germ cell cancer

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
11 Unique IMPs
0 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 1
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Platinum compound 3 substances
Macrolide / aminoglycoside 1 substance
Topoisomerase II inhibitor 1 substance
Alkylating agent 1 substance
Colony-stimulating factor 1 substance
Taxane 1 substance
Phase II: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

3 trials
  • Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL Academic
    AUTOLOGOUS TUMOUR-INFILTRATING LYMPHOCYTES
    2025-522427-10-00 1 country n=10
    Pending
  • Institut Gustave Roussy Academic
    BLEOMYCIN SULFATE; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; LENOGRASTIM; MESNA; OXALIPLATIN; PACLITAXEL
    2023-505040-19-00 1 country 2023 n=150
    Recruiting
  • The University Of Birmingham Academic
    INDOCYANINE GREEN
    2024-514089-37-00 1 country n=30
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL Academic 1 Phase II 0
Institut Gustave Roussy Academic 1 Phase II 1
The University Of Birmingham Academic 1 Phase II 0
New trials by year
2023
1
← All indication landscapes